This site is intended for U.S. healthcare professionals.

Indication
IDHIFA® (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation as detected by an FDA-approved test.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

EXPLORE OUR MOA

MANAGING PATIENTS ON IDHIFA®

WATCH A THEORETICAL PATIENT CASE AND RESULTS FROM THE PIVOTAL TRIAL

  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V1.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed April 14, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.